Clinical Observation on Antiruisi Prescription (安替瑞丝方) in Preventing Restenosis after Coronary Artery Stenting

Antiruisi (AR)prescription (安替瑞丝方) is a compound in Chinese drug-therapy, which was used to treat 35 patients with coronary heart disease after stenting by the authors, and a satisfactory effect had been proved in preventing restenosis. It is reported as follows.

安替瑞丝方防治再狭窄的生化机制研究

目的 研究安替瑞丝方防治再狭窄的生化机制。方法 健康雄性新西兰白兔29只,随机分为假手术组(n=9)、模型组(n=9)、治疗组(n=11),采用兔右侧髂动脉进行球囊扩张加高脂饲养的方法,制作动脉狭窄模型,然后进行PTA治疗,并停用高脂饲养4周。观察治疗前后血清胆固醇(TC)、三酰甘油(TG)、组织纤溶酶原激活物(tPA)、纤溶酶原激活抑制物(PAI)、内皮素(ET)、一氧化氮(NO)水平的变化及各因素与再狭窄发生率的相关性。结果 模型组和对照组比较,疗程结束后两组TC分别为(482±205) mg%和(270±156) mg%(P<0.05);ET分别为(203±47) pg%和(138±25)pg%(P<0.001);TG、tPA、PAI、NO组间差异无统计学意义,而且再狭窄发生率只与ET水平呈正相关(P<0.05)。结论 安替瑞丝方能够通过降低血清TC和ET水平抑制再狭窄的发生。